UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

SAMSUNG BIOEPIS CO., LTD., CELLTRION INC,
and BIOCON BIOLOGICS INC.
Petitioners,

v.

REGENERON PHARMACEUTICALS, INC.,
Patent Owner.

Patent No. 11,253,572

Inter Partes Review No. IPR2023-00884[1]

DECLARATION OF JEREMY COBB

[1] IPR2024-00260 and IPR2024-00298 are joined with IPR2023-00884.

I, Jeremy Cobb, do hereby declare as follows:

1. I am a member in good standing of the Maryland State Bar (2012) and the District of Columbia Bar (2013), as well as the following federal court: U.S. Court of Appeals for the Federal Circuit (2012).

2. I am a partner at the law firm of Arnold & Porter Kaye Scholer LLP ("Arnold & Porter"). I began working at Arnold & Porter in October 2021, and prior to that was an associate at Covington & Burling LLP for nine years.

3. I am an experienced litigating attorney with over 12 years in private law practice, and substantial experience with patent litigation. I have been counsel in at least fifteen patent infringement matters, including in various district courts across the country, the Patent Trial & Appeal Board, and the Federal Circuit. My patent litigation experience includes cases related to biologics and small molecules.

4. I have never been suspended or disbarred from practice before any court or administrative body.

5. I have never had an application for admission to practice before any court or administrative body denied.

6. I have had no sanctions or contempt citations imposed against me by any court or administrative body.

7. I have read and will comply with the Office Patent Trial Practice Guide and the Board's Rules of Practice for Trials set forth in 37 C.F.R. § 42.

8. I agree to be subject to the USPTO Rules of Professional Conduct set forth in 37 C.F.R. §§ 11.101 *et seq.* and disciplinary jurisdiction under 37 C.F.R. § 11.19(a).

9. I have applied to appear *pro hac vice* in the following other proceedings before the USPTO: IPR2016-00458, IPR2021-00880, IPR2021-00881, IPR2022-01225, IPR2022-01226, and IPR2023-00442. The USPTO granted my *pro hac vice* application in IPR2016-00458, IPR2021-00880, IPR2021-00881, IPR2022-01225, IPR2022-01226, and IPR2023-00442.

10. Adam R. Brausa (Reg. No. 60,287) is an experienced registered patent attorneys with whom I have worked closely and will continue to do so.

11. I have significant familiarity with the subject matter at issue in this proceeding and have substantive knowledge of the patent at issue (U.S. Patent No. 11,253,572 (the "'572 Patent")) by virtue of my preparation for this proceeding. A significant amount of my time since October 2021 has been spent working on issues related to the '572 Patent, related patents, and Patent Owner's commercial product, Eylea. Therefore, I have a substantial familiarity with the subject matter of this proceeding.

12. In addition, I have a Bachelor's of Science degree in chemistry from Butler University, a Master's degree in organic chemistry from the University of Illinois-Urbana Champaign, and I worked in the pharmaceutical industry as a research scientist for five years.

13. I hereby declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct, and that all statements made of my own knowledge are true and that all statements made on information and belief are believed to be true. I understand that willful false statements are punishable by fine or imprisonment or both. See 18 U.S.C. § 1001.

Dated: March 13, 2024

/Jeremy Cobb/
Jeremy Cobb